Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 232-244 , November 2008

Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications

  • Antonio Lopez–Beltran, MD, PhD

      Affiliations

    • Unit of Anatomic Pathology, Department of Surgery, Faculty of Medicine, Cordoba, Spain
    • Corresponding Author InformationAddress reprint requests and correspondence: Antonio Lopez-Beltran, MD, PhD, Unit of Anatomical Pathology, Faculty of Medicine, E-14004 Cordoba, Spain
    • ,
  • Ziya Kirkali, MD

      Affiliations

    • Department of Urology, School of Medicine, Dokuz Eylül University, Izmir, Turkey
    • ,
  • Liang Cheng, MD

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • Lars Egevad, MD

      Affiliations

    • Tissue Biomarkers Group, International Agency for Research on Cancer (IARC), Lyon, France
    • ,
  • Juan C. Regueiro, MD

      Affiliations

    • Urology Service, Reina Sofia University Hospital, Cordoba, Spain
    • ,
  • Ana Blanca, PhD

      Affiliations

    • Uro-Oncology Laborator, Biomedical Research Unit, Reina Sofia University Hospital, Cordoba, Spain
    • ,
  • Rodolfo Montironi, MD, FRCPath

      Affiliations

    • Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, Ancona, Italy

References 

  1. Cross S. The molecular pathology of new anti-cancer agents. Curr Diagn Pathol. 2005;11:329–339
  2. Lam JS, Leppert JT, Belldegrun AS, et al. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 2005;23:202–212
  3. Lam JS, Leppert JT, Figlin RA, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005;66:1–9
  4. Ladanyi M. Targeted therapy of cancer: new roles for pathologists. Mod Pathol. 2008;21(suppl 2):S1
  5. Lam JS, Yamashiro J, Shintaku IP, et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005;11:2591–2596
  6. Leppert JT, Lam JS, Pantuck AJ, et al. Carbonic anhydrase IX and the future of molecular markers in renal cell carcinoma. BJU Int. 2005;96:281–285
  7. Lexander H, Franzen B, Hirschberg D, et al. Differential protein expression in anatomical zones of the prostate. Proteomics. 2005;5:2570–2576
  8. Lexander H, Palmberg C, Auer G, et al. Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol. 2005;27:263–272
  9. Lexander H, Palmberg C, Hellman U, et al. Correlation of protein expression (Gleason score and DNA ploidy in prostate cancer). Proteomics. 2006;6:4370–4380
  10. Agarwal PK, Black PC, McConkey DJ, et al. Emerging drugs for targeted therapy of bladder cancer. Expert Opin Emerg Drugs. 2007;12:435–448
  11. Barbisan F, Santinelli A, Mazzucchelli R, et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer. 2008;112:636–644
  12. Barry M, Perner S, Demichelis F, et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology. 2007;70:630–633
  13. Billerey C, Chopin D, Aubriot-Lorton MH, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955–1959
  14. Biroccio A, D'Angelo C, Jansen B, et al. Antisense clusterin oligodeoxynucleotides increase the response of HER-2 gene amplified breast cancer cells to Trastuzumab. J Cell Physiol. 2005;204:463–469
  15. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer: an update. Urol Oncol. 2007;25:433–438
  16. Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis: translation from murine model to clinical trial. Cancer Metastasis Rev. 2007;26:623–634
  17. Blehm KN, Spiess PE, Bondaruk JE, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006;12:4671–4677
  18. Bono AV, Mazzucchelli R, Ferrari I, et al. Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months. J Clin Pathol. 2007;60:443–446
  19. Bradley DA, Dunn R, Nanus D, et al. Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clin Genitourin Cancer. 2007;5:460–463
  20. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536–4541
  21. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res. 2006;12:6296s–6300s
  22. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679–689
  23. Lopez Beltran A, Cheng L, Mazzucchelli R, et al. Morphological and molecular profiles and pathways in bladder neoplasms. Anticancer Res. 2008;(in press)
  24. Lopez–Beltran A, Alvarez–Kindelan J, Luque R, et al. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium. J Pathol. 2008;215:263–272
  25. Lopez–Beltran A, Maclennan GT, de la Haba-Rodriguez J, et al. Research advances in apoptosis-mediated cancer therapy: a review. Anal Quant Cytol Histol. 2007;29:71–78
  26. Lopez–Knowles E, Hernandez S, Kogevinas M, et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res. 2006;12:6029–6036
  27. Lopez–Knowles E, Hernandez S, Malats N, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66:7401–7404
  28. Demichelis F, Fall K, Perner S, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007;26:4596–4599
  29. Demichelis F, Rubin MA. TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol. 2007;60:1185–1186
  30. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134
  31. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13:1801–1809
  32. Filosa A, Fabiani A. Angiogenesis and molecular markers as specific therapeutic tragets in renal cell cancer. Anal Quant Cytol Histol. 2008;30:185–186
  33. Gandour-Edwards R, Lara PN, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer. 2002;95:1009–1015
  34. Glaessgen A, Jonmarker S, Lindberg A, et al. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer. APMIS. 2008;(in press)
  35. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol. 2005;23:38–46
  36. Gleave M, Miyake H, Chi K. Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancer. Cancer Chemother Pharmacol. 2005;56(suppl 1):47–57
  37. Gleave ME, Monia BP. Antisense therapy for cancer. Nat Rev Cancer. 2005;5:468–479
  38. Gollob JA, Rathmell WK, Richmond TM, et al. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer. J Clin Oncol. 2007;25:3288–3295
  39. Haas NB, Uzzo RG. Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer. Curr Treat Options Oncol. 2007;8:211–226
  40. Haas NB, Uzzo RG. Targeted therapies for kidney cancer in urologic practice. Urol Oncol. 2007;25:420–432
  41. Hadaschik BA, Gleave ME. Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol. 2007;25:413–419
  42. Hadaschik BA, Sowery RD, Gleave ME. Novel targets and approaches in advanced prostate cancer. Curr Opin Urol. 2007;17:182–187
  43. Hernandez S, Lopez–Knowles E, Lloreta J, et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006;24:3664–3671
  44. Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006;10:321–330
  45. Hofer MD, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia. 2004;6:503–512
  46. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281
  47. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004–7014
  48. Cheng L, Bishop E, Zhou H, et al. Lymphatic vessel density in radical prostatectomy specimens. Hum Pathol. 2008;39:610–615
  49. Chi KN, Eisenhauer E, Fazli L, et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst. 2005;97:1287–1296
  50. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 2000;60:7099–7105
  51. Jimenez RE, Hussain M, Bianco FJ, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7:2440–2447
  52. Kassouf W, Luongo T, Brown G, et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol. 2006;176:787–792
  53. Kim SJ, Uehara H, Yazici S, et al. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst. 2006;98:783–793
  54. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res. 2005;304:417–431
  55. Lin AM, Rini BI, Weinberg V, et al. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006;98:763–769
  56. Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol. 2003;170:593–594
  57. Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J Urol. 2003;170:2163–2172
  58. Mamane Y, Petroulakis E, LeBacquer O, et al. mTOR, translation initiation and cancer. Oncogene. 2006;25:6416–6422
  59. Marks RA, Zhang S, Montironi R, et al. Epidermal growth factor receptor (EGFR) expression in prostatic adenocarcinoma after hormonal therapy: a fluorescence in situ hybridization and immunohistochemical analysis. Prostate. 2008;68:919–923
  60. Mehra R, Tomlins SA, Yu J, et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res. 2008;68:3584–3590
  61. Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995;153:919–925
  62. Miyake H, Hara I, Gleave ME. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic. Int J Urol. 2005;12:785–794
  63. Miyake H, Hara I, Yamanaka K, et al. Introduction of insulin-like growth factor binding protein-2 gene into human bladder cancer cells enhances their metastatic potential. Oncol Rep. 2005;13:341–345
  64. Montironi R, Mazzucchelli R, Barbisan F, et al. Immunohistochemical expression of endothelin-1 and endothelin-A and endothelin-B receptors in high-grade prostatic intraepithelial neoplasia and prostate cancer. Eur Urol. 2007;52:1682–1689
  65. Montironi R, Mazzucchelli R, Lopez–Beltran A, et al. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol. 2007;4:321–332
  66. Moon C, Park JC, Chae YK, et al. Current status of experimental therapeutics for prostate cancer. Cancer Lett. 2008;266:116–134
  67. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20:2376–2381
  68. Motzer RJ, Basch E. Targeted drugs for metastatic renal cell carcinoma. Lancet. 2007;370:2071–2073
  69. Motzer RJ, Bukowski RM. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 2006;24:5601–5608
  70. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25:3958–3964
  71. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124
  72. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16–24
  73. Motzer RJ, Michaelson MD, Rosenberg J, et al. Sunitinib efficacy against advanced renal cell carcinoma. J Urol. 2007;178:1883–1887
  74. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–2524
  75. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–116
  76. Nelson JB. Endothelin inhibition: novel therapy for prostate cancer. J Urol. 2003;170:S65–S67
  77. Nelson JB, Nabulsi AA, Vogelzang NJ, et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol. 2003;169:1143–1149
  78. Patard JJ, Pouessel D, Bensalah K, et al. Targeted therapy in renal cell carcinoma. World J Urol. 2008;26:135–140
  79. Patel PH, Chadalavada RS, Chaganti RS, et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215–7220
  80. Rubin MA. Targeted therapy of cancer: new roles for pathologists–prostate cancer. Mod Pathol. 2008;21(suppl 2):S44–S55
  81. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  82. Paterson JL, Li Z, Wen XY, et al. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma. Br J Haematol. 2004;124:595–603
  83. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007;31:882–888
  84. Petroulakis E, Mamane Y, Le Bacquer O, et al. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer. 2006;94:195–199
  85. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:2505–2512
  86. Rocchi P, Beraldi E, Ettinger S, et al. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 2005;65:11083–11093
  87. Rocchi P, So A, Kojima S, et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 2004;64:6595–6602
  88. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107:2617–2621
  89. Rosenblatt R, Valdman A, Cheng L, et al. Endothelin-1 expression in prostate cancer and high-grade PIN. Anal Quant Cytol Histol. 2008;(in press)
  90. Sakamoto S, Ryan AJ, Kyprianou N. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem. 2008;103:691–708
  91. Santinelli A, Mazzucchelli R, Barbisan F, et al. α-Methylacyl coenzyme A racemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol. 2007;128:657–666
  92. Setlur SR, Mertz KD, Hoshida Y, et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008;100:815–825
  93. Shariat SF, Kattan MW, Traxel E, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992–1999
  94. Shariat SF, Khoddami SM, Saboorian H, et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy. J Urol. 2004;171:1122–1127
  95. So A, Gleave M, Hurtado-Col A, et al. Mechanisms of the development of androgen independence in prostate cancer. World J Urol. 2005;23:1–9
  96. So A, Rocchi P, Gleave M. Antisense oligonucleotide therapy in the management of bladder cancer. Curr Opin Urol. 2005;15:320–327
  97. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177:1258–1263
  98. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia. 2008;10:177–188
  99. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–648
  100. Tomlinson DC, Baldo O, Harnden P, et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol. 2007;213:91–98
  101. Tomlinson DC, Hurst CD, Knowles MA. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 2007;26:5889–5899
  102. Tomlinson DC, L'Hote CG, Kennedy W, et al. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 2005;65:10441–10449
  103. van Rhijn BW, Lurkin I, Radvanyi F, et al. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001;61:1265–1268
  104. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol. 1993;10:302–313
  105. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401–409
  106. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099–7109
  107. Yamanaka K, Gleave ME, Hara I, et al. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model. Mol Cancer Ther. 2005;4:187–195
  108. Yamanaka K, Rocchi P, Miyake H, et al. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther. 2005;4:1689–1698
  109. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427–434
  110. Pan CX, Yang XJ, Lopez–Beltran A, et al. c-kit Expression in small cell carcinoma of the urinary bladder: prognostic and therapeutic implications. Mod Pathol. 2005;18:320–323
  111. Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007;13:953–957

PII: S0740-2570(08)00060-9

doi: 10.1053/j.semdp.2008.07.006

Seminars in Diagnostic Pathology
Volume 25, Issue 4 , Pages 232-244 , November 2008

Article Tools

* Image Usage & Resolution